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A b s t r A c t
bAcKGrOUND: Standardized low resolution brain electric tomography (sLORETA) is 
a validated neuroimaging method for localizing the electric activity in the brain based 
on multichannel surface electroencephalogram (EEG) recordings, having the benefit 
of improved time resolution of EEG measurements, better than that of functional 
magnetic resonance imaging (fMRI), and with a spatial resolution similar to that of 
fMRI.
ObJEctIVE: The purpose of this electrophysiological neuroimaging study was to pro-
vide a deeper mechanistic understanding of both olanzapine and risperidone pharma-
codynamics relative to gender. In doing so, we age-matched 22 men and women and 
initially evaluated their resting-state EEG recordings and later used sLORETA to 
visualize the differences in brain activity amongst the two patient groups.
MEtHODs: In this investigation, EEG data were analyzed from male and female 
schizophrenia patients treated with either olanzapine or risperidone, both atypical 
antipsychotics, during their in-patient stay at the Department of Psychiatry. Twenty-
two males and females were age-matched and EEG recordings were analyzed from 19 
silver/silver chloride electrodes. Thirty-seconds of resting EEG were spectrally trans-
formed into sLORETA. Three-dimensional statistical non-paramentric maps for the 
sLORETA global field power within each band were finally computed.
rEsULts: The results indicated that, relative to males patients, females schizophrenia 
patients had increased neuronal synchronization in delta frequency, slow-wave, EEG 
band located in the dorsolateral prefrontal cortex, within the middle frontal gyrus 
(t= -2.881, p <0.03580). These findings suggest that females experience greater do-
pamine receptor and serotonin receptor neuronal blockade relative to age-matched 
males. Further, our findings provided insight to the pharmacodynamics of second-
generation antipsychotics olanzapine and risperidone.
cONcLUsION: When compared to male patients, female patients suffering from schiz-
ophrenia have dopamine and serotonin receptors that are blocked more readily than 
age-matched male schizophrenia patients. Clinically, this may translate into a quicker 
time to treatment-response in females as compared to male patients.
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I N t r O D U c t I O N
Men and women are alike in many ways. However, it is 
clear that there are gender differences in in the basic medical 
science areas of reproductive anatomy, physiology, and in bio-
chemistry. From a clinical laboratory perspective, measures of 
hemoglobin, estrogen, testosterone and more provide recom-
mended threshold levels, often based on both age and gender. 
However, often times, when prescribing medication, dosage 
recommendations are often not clearly defined. Moreover, in 
the area of psychopharmacology, clinicians often titrate doses 
in hopes of ameliorating symptoms of psychosis and to achieve 
therapeutic benefits for their male and female patents, pre-
scribed the same drug. From a neurophysiological perspective, 
are these differences able to be visualized or even quantified 
in the brain? There has been mounting evidence during both 
resting-state and cognitive-task related electroencephalograms 
(EEGs), suggesting that several regions in the cerebral cortex 
have been identified as dysfunctional in schizophrenia and 
other psychotic disorders.1,2 Moreover, there has been an 
increasing interest in understanding the foundations of the 
resting-state EEG networks due to evidence that the variations 
are highly sensitive for diagnostic associations, in genetic, and 
in different cognitive states.3
For several decades, investigators have consistently ob-
served increases in delta frequency band and theta frequency 
band activity in patients diagnosed with schizophrenia.4–6 
However, in general pharmacology and therapeutics, women 
experience a higher frequency of adverse drug reactions than 
men.7 Moreover, gender differences in the metabolism of anti-
psychotic drugs have been reported potentially related to gen-
der-specific genetic differences in cytochrome P450 enzymes 
which may point to marked genetic polymorphisms.8 In this 
investigation, we control for both gender and age in patients 
diagnosed with schizophrenia to identify electrophysiological 
neuroimaging differences of atypical antipsychotic drugs block-
ing both serotonin 5HT2A and dopamine D2 receptors. In 
order to achieve this, we used the standardized low resolution 
brain electric tomography software (sLORETA), a validated 
method for localizing the electric activity in the brain based on 
multichannel surface EEG recordings.9,10 sLORETA has the 
benefit of improved time resolution of EEG measurements 
of milliseconds, which is 3-fold better than that of functional 
magnetic resonance imaging (fMRI), with spatial resolution 
which is similar to that of fMRI (~7 mm).
M E t H O D s
PA t I E N t s
All patient data were obtained from a large database of 
EEGs from the Department of Psychiatry’s Neurophysiol-
ogy Study Laboratory of the Medical University of Lublin 
in Poland. All patients were diagnosed by a board-certified 
Psychiatrist using the diagnostic criteria from the World 
Health Organization’s International Statistical Classification 
of Diseases and Related Health Problems (ICD-10) section on 
Mental, Behavioral, and Neurodevelopmental Disorders. Our 
study included 22 male and 22 female schizophrenia patients 
who were age-matched (mean age = 22 ± 6.6 years). Patient 
EEG recordings were then classified and categorized by both 
gender and the ICD-10 diagnosis. Similarly, each patient’s 
birth-month was recorded in an effort to identify any associa-
tions of seasonality of birth psychiatric illness based on gender. 
Pharmacologically, all patients were medicated with second 
generation, atypical antipsychotics, including olanzapine 
(dose 5 – 20 mg/day) or risperidone (dose 1 – 4 mg/day). Both 
of these medications are known to block dopamine D2 and 
serotonin 5-HT2 receptors in the central nervous system and 
have shown tremendous success in the management of patients 
with schizophrenia. This research protocol was approved by the 
Bioethical Commission of the Medical University of Lublin.
E E G  r E c O r D I N G s
All patients were comfortably seated at a semi-recumbent 
position in a sound and light attenuated room, while 20 minutes 
or more of routine eyes-open and eyes-closed resting EEG data 
were recorded using the 19-channel EEG Analysis Station (EL-
MIKO Medical, Poland) and silver-silver chloride (Ag/AgCl) 
electrodes. Patient EEG recordings were in accordance to the 
international 10/20 system with electrodes placed at positions 
identified as Fp2, F8, T8/T4, P8/T6, O2, F4, C4, P4, Fp1, F7, 
T7/T3, P7/T5, O1, F3, C3, P3, Fz, Cz, and Pz; letters F, T, C, 
P and O standing for frontal, temporal, central, parietal, and 
occipital lobes, respectively (N.B.: there exists no central lobe, 
letter C is used only for identification purposes, and letter z, 
standing for zero, refers to an electrode placed on the midline). 
Even numbers (2, 4, 6, 8) refer to electrode positions on the 
right hemisphere, whereas odd numbers (1, 3, 5, 7) refer to 
positions on the left hemisphere. Letter codes A, Pg and Fp 
identify the earlobes, nasopharyngeal and frontal polar sites 
respectively. The nasion (depressed area between the eyes, just 
above the nose bridge) and the inion (lower point of the skull 
at the back of the head) were the two anatomical landmarks 
used for the positioning of the EEG electrodes.
Electrodes were referenced to linked earlobes and imped-
ances were kept below 5 kΩ. The data sampling rate was 250 
Hz, and the acquired signals were filtered with a band-pass fil-
ter of 0.15–70 Hz after sampling. Prior to data analysis, artifact 
detection was performed, visually, to exclude eye-movements, 
head-movements, muscle-movements, and segments of de-
creased alertness. EEG recordings were then exported using 
ELMIKO’s EEG DigiTrak Analysis software to the ASCII 
format for later processing.
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N E U r O I M A G I N G  –  L O r E t A
Following the export of the ASCII formatted data from 
the ELMIKO EEG acquisition system, 30-seconds of eyes-
open EEG signals were recomputed to the average reference. 
Subsequently, spectral analysis was performed for the same 
30-seconds of artifact-free data of each ICD-10 diagnostic 
group. The cross-spectra were averaged across the 50% over-
lapping windows, which yielded 7 EEG frequency bands: delta 
(1.5–6 Hz), theta (6.5–8 Hz), alpha-1 (8.5–10 Hz), alpha-2 
(10.5–12 Hz), beta-1 (12.5–18 Hz), beta-2 (18.5–21 Hz) and 
beta-3 (21.5–30 Hz).11 Lastly, low resolution brain electro-
magnetic tomography (LORETA) was used to estimate the 
3-dimensional intracerebral current density distribution.9,10
The three-dimensional intracerebral neuronal source 
activity, illustrating statistical non-parametric maps of neuro-
nal activity, are derived from the 19-channel electrodes were 
assessed using LORETA.10 When considering the available 
methodologies of detecting intracerebral activity, it is impor-
tant to note that of all available published three-dimensional, 
discrete, distributed, linear EEG/Magnetoecephalography 
(MEG) tomography methods for solving the classic EEG 
inverse problem, LORETA has been identified to report 
the lowest localization error (to within 1 voxel resolution on 
average).10 The source localization results from LORETA, 
even without utilizing an individual patient’s MRI anatomical 
scans, has demonstrated that with as many as 16-electrodes, 
and using the approximate three-shell head model registered 
to the Talairach human brain,12 localization accuracy of EEG 
is 10 mm, for worst cases.13 By adding the expected localiza-
tion error, as a result of the head model, the average error is 
not expected to exceed 2 to 3 cm in the final LORETA source 
localization results. LORETA inverse solutions are a model of 
the 3D distribution of electric neuronal activity, represented 
by adjacent voxels, has maximum synchrony relative to the 
orientation and strength between neighboring neuronal popu-
lations.10 LORETA inverse solutions are restricted to 2394 
voxels (spatial resolution = 7 mm) within cortical gray matter 
and hippocampi, as determined by the digitized Talairach and 
probability atlases of the Brain Imaging Centre, Montreal 
Neurological Institute (MNI305).
EEG electrode coordinates are derived from cross-reg-
istrations between spherical and head geometry.14 Concern-
ing the validity of the neuronal activation results, currently, 
LORETA has received robust theoretical and cross-modal 
validation from localization studies combining this method 
with both structural and fMRI, positron emission tomography 
(PET), visual and auditory event-related potentials, and well 
as intracranial recordings.11
In our investigation of the gender-based diagnostic (ICD-
10) group differences, standardized LORETA (sLORETA)10 
was used to evaluate the pharmacodynamic differences of 
risperidone and olanzapine, both atypical neuroleptics, in pa-
tients being treated for schizophrenia. The sLORETA inverse 
solutions are constrained to the MNI15215 template composed 
of 6239 cortical gray matter voxels at 5mm spatial resolution 
and provides tremendous accuracy in source localization.
The sLORETA software package was used as a new im-
provement relative to LORETA. With sLORETA, realistic 
scalp electrode coordinates are adapted to a 10/5 electrode 
system16 and are registered to the Montreal Neurological 
Institute’s MNI15215 scalp, with a 12-parameter transforma-
tion followed by a spline solution that projects the electrodes 
onto the scalp with minimal distortion.17 By transforming 
the electrode system, sLORETA provides a much more re-
alistic head-surface based coordinate system. Moreover, the 
sLORETA transformation matrix for the inverse solution uses 
the electric potential lead field computed within the boundary 
element method applied to the MNI152 digitized structural 
MRI template.18 Further, the identified sLORETA inverse 
solutions are reported on MNI152 template which is composed 
of 6239 cortical gray matter voxels at 5 mm with anatomical 
labels as Brodmann areas are also reported using MNI space, 
with correction to Talairach space.19
s t A t I s t I c A L  A N A Ly s I s
The demographic differences between the patient groups 
were graphically represented using Microsoft Excel. The 
localization of the differences in activity between the groups 
included 22 male schizophrenia patients and 22 female schizo-
phrenia patients was assessed by voxel-by-voxel non-paired 
t-tests of the LORETA images, based on the log-transformed 
power of the estimated electric current density, which resulted 
in t-statistic 3-dimensional images. In these images, cortical 
voxels of statistically significant differences were displayed 
as statistical parametric maps (SPMs) using a randomization 
strategy that determined the critical probability threshold 
values for the actually observed statistic with corrections for 
multiple testing.20
To visualize the global distributions of the t-test differ-
ences, for each band we computed the location of the mean 
center of gravity of all voxels with positive and negative t-
values. To correct for multiple comparisons, a nonparametric 
single-threshold test was applied on the basis of the theory of 
randomization and on permutation tests.20 The omnibus null 
hypothesis of no activation anywhere in the brain was rejected 
if at least one t-value (i.e. voxel, t-max) was above the critical 
threshold for p = 0.05, determined by 5,000 randomizations.21
r E s U L t s
The results of the standard low resolution brain electroto-
mography (sLORETA) statistics are provided in Table 1. 
These results of the brain mapping pathway, which is illustrated 
in Figure 1, indicate that 22 female schizophrenia patients ex-
hibited greater neuronal synchrony along both the dopamine 
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FIGUrE 1. Atypical antipsychotic pathway of dopamine D2 and sertonin 5HT2 receptors. Blue colors indicate hypofunction of neu-
rons in female schizophrenia patients compared to age-matched male schizophrenia patients.
tAbLE 1. Patient group results of sLORETA analysis between the age-matched 22 schizophrenia male versus 22 schizo-
phrenia female patients.
sLOrEtA brain Mapping results
Patient Group with the Statistically Significant  
Neuronal Synchronization
22 Female Schizophrenia Patients 
Whole Brain Voxel-wise t-test Result t= -2.881
p-Value p=0.0358
Frequency Band Delta (1.5 Hz – 6 Hz)
Neuroanatomical Locations(s) Right Middle Frontal Gyrus (Dorsolateral Prefrontal Cortex)
Lobe Frontal Lobe
Brodmann Area 10
Montreal Neurological Institute Coordinates X=30, Y=55, z=25
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FIGUrE 2. Resting state neuroimaging findings illustrating the action of atypical antipsychotics on post-synaptic dopamine D2 
receptors following whole brain voxel-by-voxel non-paired t-statistic analysis that are based on the power of estimated electric current 
density statistical non-parametric map (SnPM) of sLORETA images in 22 schizophrenia females. The blue/cyan shades indicate 
decreased neuronal activity in the delta frequency band in the right middle frontal gyrus (Brodmann Area=10; MNI Coordinates 
(mm): X=30, Y=55, z=25) along the dopamine mesocortical pathway. Structural anatomy is shown in grey scale (A: anterior; S: 
superior; P: posterior; L: left; R: right).
FIGUrE 3. Resting state EEG neuroimaging findings illustrat-
ing dopamine D2 post-synaptic receptor blockade in female 
schizophrenia on medicated with atypical antipsychotics.
(D2) and serotonin (5-HT2) containing neurons projecting 
from the rectal gyrus to the clinically relevant middle frontal 
gyrus. The neuroimaging findings, shown in Figure 2, provide 
axial, sagittal, and coronal neuroanatomical correlations for 
visualizing the pharmacodynamics of atypical antipsychotics 
in schizophrenia females versus males. Further evaluating the 
pharmacodynamics, relative to the 7 EEG frequency bands, 
the whole-brain voxel-by-voxel analysis provided statistically 
significant voxel differences, within the delta frequency band 
(1.5 Hz-6 Hz). Clinically, this illustrates a quieting/sedating 
effect of the atypical antipsychotics in the resting-state of 
the female patients more so than in the male patients. This 
provides further insight that men would generally require 
higher dosages, relative to age-matched females, to achieve 
similar pharmacodynamic results as would females at standard 
dosages.
The age-matched female patients showed slow-wave activa-
tion specifically in the dorsolateral prefrontal cortex (DLPFC), 
right middle frontal gyrus (t= -2.881, p=0.0358). The neuroana-
tomical location of the DLPFC provides tremendous clinical 
insight and activation along the dopaminergic and serotonergic 
pathway along the medial aspects of the brain to both clinical 
response and target locations during future drug discovery 
protocols. Generally, the results indicate that, relative to the 
age-matched males, females exhibited increased neuronal 
synchrony, to the same class of antipsychotics, when target-
ing the same receptors (D2 and 5HT2), as shown in Figure 3. 
Moreover, our findings are fairly consistent with many studies 
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which have found an increase in current density in the delta 
frequency band in patients with schizophrenia in comparison 
to control groups, suggesting hypofrontality in female patients 
suffering from schizophrenia.22–26 such as delta band activity, in 
specific brain regions are associated with psychotic symptoms. 
Data were obtained from 17 neuroleptic-naive patients with 
schizophrenia and age- and sex-matched 17 healthy control 
subjects. Low Resolution Brain Electromagnetic Tomogra-
phy (LORETA Overall, the findings illustrate that second 
generation antipsychotic drugs block dopamine D2-receptors, 
more readily in female patients, relative to male patients, 
being administered similar dosing regimens in an inpatient 
psychiatric facility.
D I s c U s s I O N
M A L E  V E r s U s  F E M A L E  P H A r M A c O K I N E t I c s
In the National Institutes of Mental Health-funded Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) 
clinical trial that was focused on comparing the effectiveness 
of first-generation (available since the 1950s) antipsychotics 
to second-generation (available since the 1990s) antipsychot-
ics used to treat schizophrenia found that in schizophrenia 
patients (n=406) treated with olanzapine, men cleared the 
drug 38% faster than women (P <0.0001).27 These results 
were assessed using nonlinear mixed-effects modeling which 
determines population pharmacokinetics and suggests that our 
findings would provide a molecular imaging (D2 and 5-HT3 
neuronal pathway) insight to the role of gender to the phar-
macodynamics of second-generation antipsychotics.
In a another study conducted at two centers in Austria, 
comprising 129 patients, adjusted for 70-kg body weight, look-
ing to evaluate the influence of age and gender on risperidone 
plasma concentrations, found that even when males where 
maintained at higher daily dosages, mean 5.3 + 2.0 mg/day 
(median = 6 mg/day) as compared to females dosed at 4.8 + 
1.5 mg/day (median = 5 mg/day), plasma concentrations were 
nonetheless higher in female patients: male plasma risperidone 
levels 31.7 +18.8 ng/mL (median = 27 ng/mL) and female 
plasma risperidone levels 42.6 + 28.2 ng/mL (median = 35 ng/
mL). These pharmacokinetic findings attest to the usefulness 
of sLORETA providing neuroimaging insight for when evalu-
ating the pharmacodynamics of psychotropic medications.28
G E N D E r  D I F F E r E N c E s  I N 
P H A r M A c O D y N A M I c s  O F  A t y P I c A L 
A N t I P s y c H O t I c s
In most studies using positron emission tomography 
(PET) scans for evaluating dopamine D2 receptor occupancy, 
clinical effects, therapeutic response, as well as extrapyramidal 
symptoms of atypical antipsychotic drugs, like risperidone and 
olanzapine, differences were found with that of first generation 
antipsychotic drugs.29,30 Thus, in an effort to begin the next step 
in delivering personalized medicine based on pharmacodynam-
ics and pharmacogenomics, a proper step forward would be 
to take gender into consideration in daily clinical practice as 
well as in therapeutic drug development.
As a group in schizophrenia patients, women have higher 
antipsychotic plasma levels than men after receiving the same 
dose of drug.8 Moreover, based on our neuroimaging findings 
comparing male and female schizophrenia patients on similar 
atypical antipsychotic drug regimens, it appears that dopamine 
D2-receptor blockade is more pronounced in females as com-
pared to males. These findings are consistent with previously 
published literature suggesting females requiring lower dos-
ages of atypical antipsychotics drugs to suppress symptoms of 
psychosis.31,32 Further, our findings may suggest that aims at 
drug discovery for new psychotropic medications may want to 
focus on brain activity localized to the middle frontal gyrus, 
in an effort of potentially identifying orphan-receptors from 
second/third generation neuroleptics.
t r E A t M E N t  M A r K E r  O F  t H E r A P E U t I c 
E F F I c A c y  I N  s c H I z O P H r E N I A  PA t I E N t s
A National Institutes of Mental Health (NIMH)-funded, 
double-blind randomized, clinical trial using fMRI evaluating 
24 schizophrenia patients and 24 controls, identified that the 
right dorsolateral prefrontal cortex, as in our study, is a bio-
marker for improvement of psychotic symptoms.33 A publica-
tion in Clinical Pharmacology & Therapeutics in 2001, with the 
lead author from the National Institutes of Health in Bethesda, 
Maryland defined a biological marker (biomarker) as, “A 
characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention.”34
c O N c L U s I O N
Based on the localization of brain activity relative to atypi-
cal antipsychotic drug therapy, we have identified a marker of 
therapeutic efficacy in patients with schizophrenia, corroborat-
ing the findings of several other studies. Use of EEG neuroim-
aging, provides cost benefit and broader mechanistic insight 
into the use and clinical utility of psychotropic medications 
and may be used in parallel with PET scans in both early and 
late phase clinical trials. EEG neuroimaging provides access 
to the special populations of people suffering from obesity, 
claustrophobia, or diagnosed with developmental delay or 
autism. Young children are able to move around with an EEG 
electrode cap without affecting the results. Moreover, patients 
with metallic particles from implants, tattoos, or war shrapnel 
who are often not able to have a fMRI may benefit, as well as 
those who cannot be exposed to the radiation of PET scans.
Electrophysiological neuroimaging may serve as a useful 
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tool for the pharmaceutical industry and academia when 
needing to add an extra dimensionality of evaluating the 
pharmacogenetic differences in patients who have are poor, 
intermediate, and rapid metabolizers based on cytochrome 
P450 single nucleotide polymorphisms. Lastly, from a clinical, 
daily practice, perspective mental health professionals may 
want to monitor female patients very closely for adverse ef-
fects, more specifically in the young and elderly populations. 
Likewise, clinicians may want to consider titrating dosages 
in male patients when symptomatic improvement is lagging 
relative to female patients. EEG neuroimaging may be utilized 
and databases of patient progress may be stored as an extra 
measure of research-based insight to the standard patient 
record. The overall efforts of the research and development 
arms of the pharmaceutical industry, mental health institu-
tions, and academic medical centers globally are encourag-
ing, all with the goal of improving the care and treatment of 
patients.
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